Veru (NASDAQ:VERU) Share Price Crosses Below Two Hundred Day Moving Average – What’s Next?

Shares of Veru Inc. (NASDAQ:VERU) crossed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $3.88 and traded as low as $2.15. Veru shares last traded at $2.21, with a volume of 221,361 shares traded.

Wall Street Analyst Weigh In

Several research analysts have weighed in on VERU shares. Canaccord Genuity Group started coverage on shares of Veru in a research note on Thursday, December 18th. They issued a “buy” rating and a $25.00 price objective on the stock. Wall Street Zen upgraded shares of Veru from a “sell” rating to a “hold” rating in a report on Saturday, December 20th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Veru in a report on Wednesday, October 8th. Finally, Oppenheimer reissued an “outperform” rating on shares of Veru in a research report on Thursday, December 18th. Four investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $25.00.

Veru Trading Down 7.9%

The firm has a market cap of $35.47 million, a P/E ratio of -1.00 and a beta of -1.01. The business’s fifty day moving average price is $2.66 and its two-hundred day moving average price is $3.88.

Institutional Trading of Veru

Institutional investors and hedge funds have recently made changes to their positions in the stock. Catalyst Funds Management Pty Ltd acquired a new position in shares of Veru during the 2nd quarter valued at about $36,000. Northwestern Mutual Wealth Management Co. bought a new stake in Veru during the third quarter worth approximately $38,000. Allworth Financial LP bought a new stake in Veru during the second quarter worth approximately $45,000. Cassaday & Co Wealth Management LLC acquired a new position in Veru during the third quarter valued at approximately $47,000. Finally, XTX Topco Ltd bought a new position in shares of Veru in the second quarter valued at approximately $49,000. Institutional investors and hedge funds own 47.16% of the company’s stock.

About Veru

Veru Inc is a clinical-stage biopharmaceutical company headquartered in Miami, Florida. The company is dedicated to the development and commercialization of novel therapies in the fields of oncology and infectious disease. Veru’s research strategy centers on advancing small-molecule and biologic candidates through clinical trials, leveraging its in-house manufacturing and formulation capabilities as well as strategic partnerships to support late-stage development.

The company’s lead product candidate is sabizabulin (VERU-111), an oral, microtubule-disrupting agent undergoing pivotal trials for indications that include metastatic castration-resistant prostate cancer and hospitalized patients with severe COVID-19.